IL6 and COVID-19: Gupta S et al reported that COVID-19 patients treated with tocilizumab had a reduced risk of hospitalization.[79] However, anti-IL-6 drugs may diminish the Th17 immune response and the efficacy of phagocytic cells, leading to impaired recruitment of AMP and neutrophils vital for antifungal defense.[80,81] Theoretically, the use of anti-IL-6 drugs heightens the susceptibility of COVID-19 patients to Aspergillus infection.